The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Emerging therapies after BCMA- and GPRC5D-directed treatment in multiple myeloma
Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, discusses emerging treatment options for patients with multiple myeloma refractory to BCMA- and GPRC5D-directed therapies. He highlights the potential role of cereblon E3 ligase modulators (CELMoDs) such as iberdomide and mezigdomide, as well as emerging approaches targeting FcRH5, including cevostamab. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
